Provided by Tiger Trade Technology Pte. Ltd.

Travere Therapeutics, Inc.

56.93
+0.08000.14%
Post-market: 56.930.00000.00%19:30 EDT
Volume:1.72M
Turnover:97.82M
Market Cap:5.37B
PE:-119.49
High:57.53
Open:57.21
Low:56.34
Close:56.85
52wk High:68.73
52wk Low:22.59
Shares:94.26M
Float Shares:92.77M
Volume Ratio:1.08
T/O Rate:1.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4764
EPS(LYR):-0.2864
ROE:-236.35%
ROA:-3.73%
PB:218.84
PE(LYR):-198.81

Loading ...

Feb 12, 2021

Major Issues Report

8-K - Current report
Feb 12, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 12, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 11, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 10, 2021

Major Issues Report

8-K - Current report
Feb 10, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 04, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 02, 2021

Major Issues Report

8-K - Current report
Feb 01, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 11, 2021

Major Issues Report

8-K - Current report
Jan 04, 2021

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Nov 18, 2020

Major Issues Report

8-K - Current report
Nov 18, 2020

Major Issues Report

8-K/A [Amend] - Current report
Nov 16, 2020

Major Issues Report

8-K - Current report
Nov 12, 2020

Major Issues Report

8-K - Current report
Nov 05, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 05, 2020

Major Issues Report

8-K - Current report
Oct 22, 2020

Major Issues Report

8-K - Current report
Oct 06, 2020

Major Issues Report

8-K - Current report
Sep 21, 2020

Correspondence

CORRESP [Cover] - Correspondence